Impact of 3-month earlier versus postponed initiation of opicapone versus entacapone in levodopa-treated patients with Parkinson’s disease and motor fluctuations
Objective: This post-hoc analysis evaluated the impact of 3-month earlier versus postponed initiation of opicapone (OPC) in patients with Parkinson’s disease (PD) and motor fluctuations.…The OCEAN (OpiCapone Effect on motor fluctuations and associated pAiN) study in Parkinson’s disease: design and rationale of a randomized double-blind placebo-controlled trial
Objective: To evaluate if treatment with opicapone (OPC) in patients with Parkinson’s disease (PD) improves pain related to end-of-dose fluctuations, consequently improving patients’ well-being. Background:…The OASIS (OpicApone in Sleep dISorder) study in Parkinson’s disease: design and rationale of an open-label, single-arm, pilot trial
Objective: To evaluate the effects of opicapone (OPC) treatment on sleep disorders in patients with Parkinson’s disease (PD) and ‘wearing-off’. Background: OPC proved to be…Efficacy of opicapone according to different levodopa daily intakes in Parkinson’s disease patients with motor fluctuations
Objective: To evaluate the efficacy of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuation according to different levodopa daily intakes. Background: OPC proved…The EPSILON (Early ParkinSon wIth L-dopa/DDCi and OpicapoNe) study in early Parkinson’s disease: design and rationale of a phase III, double-blind, randomized, placebo-controlled study
Objective: This study aims to explore the potential of opicapone (OPC) to enhance the clinical benefit of levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCi) in patients with…Characterization of the pattern of daily motor fluctuations in Parkinson’s disease patients based on home diaries
Objective: Home diary-based representation of patients’ daily motor status. Background: Parkinson’s disease (PD) patients are often in their best clinical state when attending medical appointments.…Effect of opicapone and entacapone on daily pattern of motor fluctuations in Parkinson’s disease patients
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on daily pattern of motor fluctuations. Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations
Objective: To evaluate the potential added benefit of opicapone (OPC), compared with placebo (PLC) and entacapone (ENT), in catechol-O-methyltransferase inhibitor (COMTi)-naïve Parkinson’s disease (PD) patients…Onset of Drug-Related Adverse Events in Parkinson’s Disease Patients with Motor Fluctuations Treated with Opicapone in Clinical Practice: OPTIPARK Post-Hoc Analysis
Objective: This post-hoc analysis investigated the onset of treatment-emergent adverse events (TEAEs) that were considered at least possibly related to opicapone (OPC) treatment. Background: OPC…Effect of opicapone and entacapone on levodopa short duration response
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on levodopa short duration response (SDR). Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 11
- Next Page »